DOI: https://doi.org/10.14710/dimj.v4i2.20963

RECURRENCE IN NON-EPITHELIAL OVARIAN CANCER PATIENTS AT RSUP DR. KARIADI SEMARANG

*Gabriele Emi Badia  -  Department of Obstetrics and Gynecology, Faculty of Medicine Diponegoro University / Dr. Kariadi Hospital, Jl. DR. Sutomo No.16, Randusari, Kec. Semarang Sel., Kota Semarang, Jawa Tengah 50244, Indonesia
Teuku Mirza Iskandar  -  Department of Obstetrics and Gynecology, Faculty of Medicine Diponegoro University / Dr. Kariadi Hospital, Jl. DR. Sutomo No.16, Randusari, Kec. Semarang Sel., Kota Semarang, Jawa Tengah 50244, Indonesia
Suhartono Suhartono  -  Department of Environmental Health, Faculty of Public Health Diponegoro University, Jl. Prof. Jacub Rais, Tembalang, Kec. Tembalang, Kota Semarang, Jawa Tengah 50275, Indonesia
Open Access Copyright (c) 2023 Diponegoro International Medical Journal
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

BACKGROUND: Non-epithelial ovarian cancer is a very rare type, accounting for less than 10% of ovarian cancers. This type of cancer originates from germ cells or stromal-sex cord cells. Disease-free survival (DFS) in cancer is the length of time after primary treatment for cancer ends so that patients survive without signs or symptoms of cancer. Recurrence is the return of cancer that has been declared in remission, usually after a certain period in which cancer cannot be detected. Cancer can return to the same place (primary) or other parts of the body. Ovarian cancer is a disease with a high probability of recurrence, after achieving a complete response to chemotherapy, >70%. Assessment of the recurrence rate is one of the ways used to assess the effectiveness of therapy

AIM: Knowing the incidence of recurrence in patients with non-epithelial ovarian cancer who have received operative therapy with or without adjuvant chemotherapy

METHOD: Descriptive study with a case series research design and analytical works. The research sample was 50 non-epithelial ovarian cancer patients who were treated at RSUP Dr. Karadi Semarang from 2018-2019 who met the inclusion criteria and did not have exclusion criteria, 22 patients were loss of follow up during observation. The data collection technique used is total sampling. Data analysis was performed using the Chi-Square test with a significance level of p<0.05.

RESULT:  The most reported types of non-epithelial ovarian cancer were granulosa (39.3%), dysgerminoma (21.4%), yolk sac (17.9%), and mixed germ cell (17.9%). Most of the cancer cases are progressive (60.7%). There were 3 recurrence incidents happen during observation period, 2 patients with granulosa cell tumor in >50 years age group and 1 patient with Yolk Sac cell tumor in 20-50 years age group. Higher survival rates were found for tumor residues <2cm compared to >2cm at 6 months (54.5% vs 45.5%), 12 months (54.5% vs 36.4%), 18 months (45.5% vs 36.4%), and 24th month (45.5% vs 36.4%).

CONCLUSION: Optimization of surgery depends on the type of non-epithelial ovarian cancer cells, age, and the stage when the diagnosis was first established to be a factor in the incidence of recurrence.

 

Fulltext View|Download
Keywords: Non-epithelial ovarian cancer, recurrency, survival rates

Article Metrics:

Article Info
Section: Original Research Article
Language : EN
Recent articles
Correlation Between VO2 Max, Speed, and Limb Muscle Explosive Power with Agility in Soccer Players Effect of DLBS3233, Metformin, and Their Combination on the Expressions of VEGF and Endometriosis Implants in Endometriosis Mice (A Mouse Model in Endometriosis Study) RECURRENCE IN NON-EPITHELIAL OVARIAN CANCER PATIENTS AT RSUP DR. KARIADI SEMARANG Intraoperative Endoscopy as Guidance for Adequate Myotomy in Laparoscopic Heller Procedure: A Rare Case Report More recent articles
  1. Vinay K, Stanley R, Ramzi C. Robbins patologi: Sistem genitalia perempuan dan payudara. 7th ed. Jakarta: EGC; 2016
  2. Adhikari L, Hassel L. Ovary general WHO classification [Internet]. Pathology Outlines. 2021 [cited 9 August 2021]. Available from: https://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html
  3. Berek J. Berek & Novak’s Gynecology: Chapter 39: Ovarian, fallopian tube, and peritoneal cancer. 16th ed. Philadelphia: Lippincott William & Wilkins; 2020
  4. Trimukti SL. Pengaruh pengobatan pada kelangsungan hidup penderita karsinoma ovarium [Obstetrician-Gynecologist]. Diponegoro; 1994
  5. Jain S, Annett S, Morgan M, Robson T. The cancer stem cell niche in ovarian cancer and its impact on immune surveillance. International Journal of Molecular Sciences. 2021;22(4091)
  6. Tavassoli F, Devilee P. Pathology & genetics: Tumours of the breast and female genital organs. Lyon: IARC press; 2003
  7. Giornelli G, Mando P. A Theoretical view of ovarian cancer relapse. European Medical Journal. 2017;2(3)
  8. Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, et al. Non-epitelial ovarian cancers: How much do we really know? International Journal of Environmental Research and Public Health. 2022
  9. Hubbard AK, Poynter JN. Global incidence compasrisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012. Gynecologic Oncology. 2019; 154
  10. Matei D, Brown J, Frazier L. Updates in the management of ovarian germ cell tumors. American society of clinical oncology. 2013; 210
  11. Daviu C, Blaakaer J, Eriksson A, Herrstedt J, Vandborg MP, Rasmussen A, et al. Nonepitelial ovarian cancer – the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO). Acta Oncologica. 2022; 61
  12. NCCN. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Clinical Practice Guidelines. 2022;4
  13. Canlorbe G, Chabbert-Buffet N, Uzan C. Fertility-sparing surgery for ovarian cancer. Journal of Clinical Medicine. 2021;10(18)

Last update:

No citation recorded.

Last update:

No citation recorded.